CTIS2023-503606-36-00招募中1 期
CSET 2022-3571
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
A Phase 1b, placebo-controlled study to evaluate the efficacy, safety and PK of PF-07054894 in participants with moderate to severe UC.CTIS2022-501047-32-00Pfizer Inc.27
进行中（未招募）
1 期
Multicentric Phase 1 Study With Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine) or CPX-351 in Patients of 60 years old or more With adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)Adult patients with adverse Risk Acute Myeloblastic LeukemiaCTIS2022-502585-25-00Centre Hospitalier Universitaire De Nantes12
进行中（未招募）
1 期
PARP-PET in solid tumorscancer patientsMedDRA version: 20.0Level: LLTClassification code: 10027475Term: Metastatic breast cancer Class: 10029104MedDRA version: 21.1Level: PTClassification code: 10057529Term: Ovarian cancer metastatic Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10076506Term: Castration-resistant prostate cancer Class: 10029104CTIS2022-502918-87-00Karolinska University Hospital70
进行中（未招募）
1 期
A Study to Learn if the Study Medicines Called Itraconazole and Cyclosporine Change How the Body Processes the Other Study Medicine Called Danuglipron in Healthy AdultsType 2 Diabetes Mellitus, Obesity, Overweight managementMedDRA version: 20.0Level: PTClassification code: 10029883Term: Obesity Class: 100000004861MedDRA version: 24.1Level: PTClassification code: 10033307Term: Overweight Class: 100000004861MedDRA version: 20.0Level: PTClassification code: 10012601Term: Diabetes mellitus Class: 100000004861CTIS2024-513863-21-00Pfizer Inc.16
招募中
1 期
A study to learn about the taste of Vericiguat given in liquid form in healthy male participants aged 18 to 45 yearsCTIS2023-508447-52-00Bayer AG20